Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor

Yukio Sassa, Yasuaki HataDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among the aging population in the many western countries. The introdu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yukio Sassa, Yasuaki Hata
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/b76f7850d4434736b3bbd437ed9e89ab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b76f7850d4434736b3bbd437ed9e89ab
record_format	dspace
spelling	oai:doaj.org-article:b76f7850d4434736b3bbd437ed9e89ab2021-12-02T06:06:55ZAntiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor1177-54671177-5483https://doaj.org/article/b76f7850d4434736b3bbd437ed9e89ab2010-04-01T00:00:00Zhttp://www.dovepress.com/antiangiogenic-drugs-in-the-management-of-ocular-diseases-focus-on-ant-a4199https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Yukio Sassa, Yasuaki HataDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among the aging population in the many western countries. The introduction of molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, ranibizumab, and bevacizumab, as treatments for wet AMD has provided new hope for affected patients. Now we have these treatment options, which have the possibility to improve or maintain visual acuity for patients suffering from AMD. The treatment needs to be optimized and this is in progress. Based on emerging evidence, adopting a variable VEGF inhibitor-dosing strategy guided by visual acuity assessment and optical coherence tomography are now being tried to reduce the frequency of injections. VEGF inhibitors in combination with photodynamic therapy are another way to optimize treatment. Physicians are waiting for new guidelines for the management of AMD and the results of current and upcoming trials systematically addressing these issues will be expected to provide it.Keywords: age-related macular degeneration, VEGF inhibitor, verteporfin, pegaptanib, ranibizumab, bevacizumab Yukio SassaYasuaki HataDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 275-283 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Yukio Sassa Yasuaki Hata Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
description	Yukio Sassa, Yasuaki HataDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, JapanAbstract: Age-related macular degeneration (AMD) complications are the leading cause of severe vision loss among the aging population in the many western countries. The introduction of molecular inhibitors of vascular endothelial growth factor (VEGF), such as pegaptanib, ranibizumab, and bevacizumab, as treatments for wet AMD has provided new hope for affected patients. Now we have these treatment options, which have the possibility to improve or maintain visual acuity for patients suffering from AMD. The treatment needs to be optimized and this is in progress. Based on emerging evidence, adopting a variable VEGF inhibitor-dosing strategy guided by visual acuity assessment and optical coherence tomography are now being tried to reduce the frequency of injections. VEGF inhibitors in combination with photodynamic therapy are another way to optimize treatment. Physicians are waiting for new guidelines for the management of AMD and the results of current and upcoming trials systematically addressing these issues will be expected to provide it.Keywords: age-related macular degeneration, VEGF inhibitor, verteporfin, pegaptanib, ranibizumab, bevacizumab
format	article
author	Yukio Sassa Yasuaki Hata
author_facet	Yukio Sassa Yasuaki Hata
author_sort	Yukio Sassa
title	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
title_short	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
title_full	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
title_fullStr	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
title_full_unstemmed	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
title_sort	antiangiogenic drugs in the management of ocular diseases: focus on antivascular endothelial growth factor
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/b76f7850d4434736b3bbd437ed9e89ab
work_keys_str_mv	AT yukiosassa antiangiogenicdrugsinthemanagementofoculardiseasesfocusonantivascularendothelialgrowthfactor AT yasuakihata antiangiogenicdrugsinthemanagementofoculardiseasesfocusonantivascularendothelialgrowthfactor
_version_	1718400071362412544

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor

Ejemplares similares